Thousands of men are set to receive a life-prolonging prostate cancer medication through the NHS in the coming weeks. Patients diagnosed with localized cancer will soon have access to abiraterone in England as part of an expanded treatment initiative. Approximately 2,000 individuals diagnosed in the past three months will be granted access to the drug initially, with an estimated 7,000 men becoming eligible each year.
Abiraterone, an oral prescription tablet, functions by depriving the cancer cells of essential growth hormones, thereby halting its spread. Recent NHS studies have revealed that the survival rate for men on abiraterone after six years stood at 86%, compared to 77% for those on standard therapy.
The UK witnesses over 55,000 new cases of prostate cancer annually, making it the most prevalent cancer among men and the second most common overall. Cancer Research UK reports these statistics. The approval of abiraterone for a larger patient pool by NHS England underscores the government’s dedication to combating the disease.
Wes Streeting, the Health and Social Care Secretary, emphasized the government’s support for evidence-based healthcare decisions, ensuring timely and effective care for patients. The introduction of abiraterone to a broader patient group is expected to enhance survival rates and provide valuable additional years to those battling prostate cancer.
Professor Peter Johnson, the National Clinical Director for Cancer at NHS England, highlighted the potential life-changing impact of this treatment option for thousands of men with prostate cancer. The imminent availability of this life-extending treatment on the NHS is viewed as a positive step towards improving the quality and duration of patients’ lives.
Researchers at the University of Cambridge are currently developing a groundbreaking blood test that could accurately detect prostate cancer presence, aggressiveness, and the necessity for treatment. This innovative test identifies specific DNA methylation markers released by tumours, enabling doctors to assess the cancer’s status and severity more effectively.
Men who have undergone the PSA test previously may benefit from this new blood test, particularly if their PSA levels were elevated, potentially avoiding the need for invasive biopsy procedures. The introduction of this advanced blood test represents a significant advancement in prostate cancer detection and management.